Agios Pharmaceuticals (NASDAQ:AGIO) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report sent to investors on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $58.00 price target on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on the company. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Scotiabank increased their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. Royal Bank of Canada boosted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Stock Up 0.7 %

NASDAQ AGIO opened at $35.47 on Monday. Agios Pharmaceuticals has a twelve month low of $27.14 and a twelve month high of $62.58. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of 3.13 and a beta of 0.88. The business has a 50-day moving average price of $34.14 and a 200-day moving average price of $42.98.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Research analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Venturi Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals during the 4th quarter worth $33,000. GF Fund Management CO. LTD. bought a new position in Agios Pharmaceuticals during the 4th quarter worth about $39,000. Wingate Wealth Advisors Inc. purchased a new position in Agios Pharmaceuticals during the 4th quarter valued at about $53,000. Sterling Capital Management LLC raised its holdings in shares of Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,587 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 611 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.